Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All aspirin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 37% Improvement Relative Risk ICU admission -1% Aspirin for COVID-19  Zadeh et al.  Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective study in the USA Lower mortality with aspirin (not stat. sig., p=0.28) c19early.org Zadeh et al., Innovation in Aging, Dec 2022 Favors aspirin Favors control

Effect of aspirin in COVID-19 outcomes of older adults with a history of coronary artery disease

Zadeh et al., Innovation in Aging, doi:10.1093/geroni/igac059.3047
Dec 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Aspirin for COVID-19
24th treatment shown to reduce risk in August 2021
 
*, now known with p = 0.000087 from 73 studies, recognized in 2 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Retrospective 4,017 coronary artery disease patients hospitalized for COVID-19 in the USA, showing no significant difference in outcomes with low dose aspirin use.
risk of death, 37.0% lower, RR 0.63, p = 0.28.
risk of ICU admission, 1.0% higher, RR 1.01, p = 0.79.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zadeh et al., 20 Dec 2022, retrospective, USA, peer-reviewed, mean age 62.2, 8 authors.
This PaperAspirinAll
IMPACT OF OACS ON OUTCOMES OF COVID-19 INFECTION IN OLDER ADULTS WITH HISTORY OF ATRIAL FIBRILLATION
Ricardo Criado Carrero, Andrew Carl Crawford, Ali Vaeli Zadeh, Alan Wong, Ana De, Diego Diaz, Elias Collado, Joshua Larned, Amy Ai, Crim Sabuncu, Ali Vaeli Zadeh, Ricardo Criado Carrero, Noah Mandile, Marina Stukova, German Lopez, Holy Cross
diseases. Records from both groups were reviewed for the first episode of HF over 12 months following the initiation of treatment. Pearson's chi-squared test was used to compare groups. The strength of association was reported using Risk Ratios (RR). A p-value < 0.05 was deemed significant. Results: 6,446 were included in each group. The mean age, gender and ECI were indifferent. 958 (15%) of patients treated with AADs and 987 (15.3%) of patients treated with CA had a first episode of HF over a year after the treatment which was not significantly different between groups (RR=1.03, CI95% = 0.95-1.11, p=0.49). Conclusion: The modality of treatment after the first episode of AF in older population doesn't significantly affect the risk of HF over the first year.
{ 'DOI': '10.1093/geroni/igac059.3047', 'ISSN': ['2399-5300'], 'URL': 'http://dx.doi.org/10.1093/geroni/igac059.3047', 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>Advanced age and coronary artery disease (CAD) have been associated ' 'with a dismal prognosis in patients infected with COVID-19, most likely due to the virus’s ' 'thrombogenic effects. Older adults with a history of CAD have routinely used low-dose Aspirin ' '(LDA) as prevention due to their increased risk of cerebro-cardiovascular events. However, it ' 'is unclear if this population would benefit from LDA when infected with COVID-19.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>A retrospective study was conducted using the PearlDiver database ' '(PearlDiver Technologies, Fort Wayne, IN). Using ICD codes, patients aged 65–75 and ' 'Elixhauser Comorbidity Score(ECI)&amp;gt;4 with a history of CAD admitted for COVID-19 were ' 'identified. The use of LDA for 1 month before the index event was used to split the cohort ' 'into two matched groups by age, gender, ECI, and other cardiovascular diseases. Records of ' 'groups were reviewed for multiple outcomes 30 days after admission. Pearson’s chi-squared ' 'test was used to compare groups. The strength of association was reported as Risk Ratios ' '(RR).</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>4,017 patients with no difference in the mean age, gender, and ECI ' 'were included in each group. No differences present in 30-days all-cause readmission(RR=1.04, ' 'CI95% =0.92–1.17, p=0.49), mortality(RR=0.63, CI95%=0.30–1.29, p=0.28), ICU ' 'admission(RR=1.01, CI95%=0.89–1.15, p=0.79), gastrointestinal bleeding(RR=1.09, CI95% = ' '0.85–1.40, p=0.51), and intracranial hemorrhage(RR=0.69, CI95%=0.26–1.83, p=0.62) between ' 'groups.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>LDA didn’t improve the evaluated outcomes in older persons 30 days ' 'after admission. A plausible explanation is that COVID-19’s thrombogenic mechanism is likely ' 'atypical.</jats:p>\n' ' </jats:sec>', 'author': [ { 'affiliation': [ { 'name': 'Holy Cross Health-Jim Moran Cardiovascular Research Institute , ' 'Fort Lauderdale, Florida , United States'}], 'family': 'Zadeh', 'given': 'Ali Vaeli', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'University of Miami/Holy Cross Hospital , Fort Lauderdale, ' 'Florida , United States'}], 'family': 'Carrero', 'given': 'Ricardo Criado', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Holy Cross Health-University of Miami , Fort Lauderdale, Florida ' ', United States'}], 'family': 'Wong', 'given': 'Alan', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Jim Moran Cardiovascular Institute , Fort Lauderdale, Florida , ' 'United States'}], 'family': 'Mandile', 'given': 'Noah', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'University of Miami at Holy Cross , Fort Lauderdale, Florida , ' 'United States'}], 'family': 'Stukova', 'given': 'Marina', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'University of Miami at Holy Cross , Fort Lauderdale, Florida , ' 'United States'}], 'family': 'Lopez', 'given': 'German', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Holy Cross Health-Jim Moran Cardiovascular Research Institute , ' 'Fort Lauderdale, Florida , United States'}], 'family': 'Collado', 'given': 'Elias', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Holy Cross Health- University of Miami , Miami, Florida , United ' 'States'}], 'family': 'Larned', 'given': 'Joshua', 'sequence': 'additional'}], 'container-title': 'Innovation in Aging', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': { 'date-parts': [[2022, 12, 20]], 'date-time': '2022-12-20T18:30:28Z', 'timestamp': 1671561028000}, 'deposited': { 'date-parts': [[2022, 12, 21]], 'date-time': '2022-12-21T19:46:45Z', 'timestamp': 1671652005000}, 'indexed': { 'date-parts': [[2022, 12, 21]], 'date-time': '2022-12-21T20:13:26Z', 'timestamp': 1671653606322}, 'is-referenced-by-count': 0, 'issue': 'Supplement_1', 'issued': {'date-parts': [[2022, 11, 1]]}, 'journal-issue': {'issue': 'Supplement_1', 'published-print': {'date-parts': [[2022, 12, 20]]}}, 'language': 'en', 'license': [ { 'URL': 'https://creativecommons.org/licenses/by/4.0/', 'content-version': 'vor', 'delay-in-days': 49, 'start': { 'date-parts': [[2022, 12, 20]], 'date-time': '2022-12-20T00:00:00Z', 'timestamp': 1671494400000}}], 'link': [ { 'URL': 'https://academic.oup.com/innovateage/article-pdf/6/Supplement_1/850/48309640/igac059.3047.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/innovateage/article-pdf/6/Supplement_1/850/48309640/igac059.3047.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '286', 'original-title': [], 'page': '850-851', 'prefix': '10.1093', 'published': {'date-parts': [[2022, 11, 1]]}, 'published-online': {'date-parts': [[2022, 12, 20]]}, 'published-other': {'date-parts': [[2022, 11, 1]]}, 'published-print': {'date-parts': [[2022, 12, 20]]}, 'publisher': 'Oxford University Press (OUP)', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': {'primary': {'URL': 'https://academic.oup.com/innovateage/article/6/Supplement_1/850/6939246'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [ 'Life-span and Life-course Studies', 'Health Professions (miscellaneous)', 'Health (social science)'], 'subtitle': [], 'title': 'EFFECT OF ASPIRIN IN COVID-19 OUTCOMES OF OLDER ADULTS WITH A HISTORY OF CORONARY ARTERY DISEASE', 'type': 'journal-article', 'volume': '6'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit